Drugs / IHL-305
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00364143 | Sep 2006 → Jun 2011 | cancer | Yakult Honsha Co., LTD | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IHL-305 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00364143 ↗ |
| Known as | irinotecan liposome injection | “IHL-305 (irinotecan liposome injection)” NCT00364143 ↗ |
| Route | Intravenous | “intravenous administration of IHL-305” NCT00364143 ↗ |